The world’s first patients were treated with the new Edison® histotripsy system

Leading US Institutions Launch Innovative Histotripsy Liver Treatment Programs

 the manufacturer of the non-invasive Edison® histotripsy system, today announced that a patient at the University of Rochester Medical Center had was the first in the world to receive targeted treatment for liver tumors using the Edison system, following the system’s recent de novo approval from the FDA. During the same week, the Cleveland Clinic treated its first patients with liver tumors using histotripsy. HistoSonics’ Image-Guided Sonic Beam Treatment System uses proprietary technology and advanced imaging to deliver non-invasive, personalized treatments with precision and control. The science of histotripsy uses focused sonic energy to produce controlled acoustic cavitation that mechanically destroys and liquefies targeted tissue at the subcellular level.

On December 18 , Dr. Roberto Hernandez-Alejandro, head of the transplant department, Dr. Koji Tomiyama, associate professor of surgery and transplantation, and their team were the first to use the Edison system to deliver liver treatment through histotripsy to a patient suffering from recurrent liver tumors originating from the colon. “ The potential for applying histotripsy to patients with liver tumors is immense. By destroying targeted liver tumors, histotripsy paves the way to downstage cancer and divert patients to surgical resection and transplantation procedures,” said Dr. Hernandez-Alejandro. “ One of the most interesting results of our first experiment is the preservation of vessels and blood circulation, which is unique and could open a new era for liver treatments,” he added.

CH David Kwon, MD, PhD, director of minimally invasive liver surgery at the Cleveland Clinic, and his team performed their first procedure on a patient with primary colorectal disease with liver metastases, whose disease had continued to progress despite treatment with chemotherapy. “ Our initial experience allowed us to see that patients could benefit from histotripsy because it is less invasive than other treatment options and our patients reported a lack of pain after the procedure,” said Dr. Kwon. The Cleveland Clinic team led by Dr. Kwon, Dr. Federico Aucejo and Dr. Jaekeun Kim treated three patients with liver tumors resulting from different diseases.

“ Our goal has always been to make a meaningful change in the lives of our patients,” said Dr. Joe Herman, medical director. “ We are encouraged to work with the University of Rochester Medical Center and the Cleveland Clinic, who are the first to offer non-invasive histotripsy to treat their patients’ liver tumors as part of standard clinical practice. in our current mission. » HistoSonics is training key personnel and launching more than a dozen programs for its initial partners across the United States. The company believes that the novel mechanism of action of its patented technology provides significant benefits to patients, including the ability of the treated site to recover and resorb quickly. The HistoSonics platform also offers physicians the unique ability to monitor tissue destruction in real time and continuously, unlike any other modalities existing today.

For more information about the Liver Surgery and Histotripsy team at the University of Rochester Medical Center, visit the following link: University of Rochester Medical Center Liver Surgery and Transplant University of Rochester Medical School)

For more information about the Cleveland Clinic Liver Surgery team, visit: Cleveland Clinic Liver Surgery and Transplant

The Edison® System is intended for non-invasive mechanical destruction of liver tumors, including partial or complete destruction by histotripsy of unrespectable liver tumors. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition. Use of the Edison system in renal applications is limited by federal law to investigational use.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter